ATNM | Ticker Profile - Titan Protect

ATNM

Actinium Pharmaceuticals, Inc.

Healthcare · Biotechnology · ASE

$1.08

Data: 2026-05-13

✗ ETHICAL FAIL

MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$41M

Total market value of the company

Trailing P/E

0.00

Forward P/E

-2.72

Based on estimated future earnings — lower means cheaper

Rev Growth

0.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-167.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+363% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

https://www.actiniumpharma.com

Country: United States Employees: 25 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

4.2% PASS

Debt must be below 33% of total assets

Cash Ratio

118.1% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.597

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0936

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.709

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-62.7%

Historical annualised return based on price data

Max Drawdown

-88.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.11

Very low correlation to market moves

52W High

$1.95

44% below the year high

52W Low

$0.95

13% above the year low

Avg Volume

178,112

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.5%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.76

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.22

Conservative use of debt — low financial risk

Current Ratio

6.20

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

6.02

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-40,274.4%

Profit from core operations before interest and tax

Free Cash Flow

$-12,849,375

Negative — the business is spending more than it generates

Revenue (TTM)

$90,000

Total revenue over the last 12 months

Net Income

$-33,887,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$5.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-13

Before you go